Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12
Achieved dose-dependent weight reductions, with lower doses producing steady, moderate loss Experienced consistent weight improvements whether they had obesity alone or obesity with type 2 diabetes This level of weight loss is similar to early GLP-1 injection trials but delivered through a once-daily pill
This decline is accelerated by external factors like UV exposure and internal factors like stress
A realistic timeline, based on where the Phase 3 programme is now, looks like this: FDA submission in the U.S.: late 2026 or 2027 FDA approval: 2027 or 2028 UK MHRA review: typically 12 to 24 months after FDA approval NHS access through a NICE appraisal: a separate process, usually 12 to 24 months after MHRA approval The earliest UK private access through online pharmacies, mirroring how Mounjaro and Wegovy first launched here, is likely 2027 or 2028
GLP-1 dosing Your healthcare professional will be able to advise on the appropriate prescription dose of GLP-1s, whether youre: Starting the medication Building up your dose over time Pausing the medication Gradually reducing your dose In general, the medications are first prescribed at the lowest dose, gradually increasing the dose over time
How do GLP-1 injections help you lose weight
